(NAPSA)—A growing number of investors are improving the health of their portfolios by stocking up on pharmaceuticals. And key to this trend is the proliferation of recombinant protein drugs—the fastest-growing segment of the pharmaceutical industry. One of the leaders in the development of recombinant protein drugs is a company with strong government support, a talented pool of scientists and low production costs. And though it is based in the Far East, the companyis actively securing funding in Western capital markets. SinoBiomed, Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, the company currently has 10 products approved or in development: two on the market, one awaiting approval, four in clinical trials and three in research and development. The company’s products respond to a wide range of diseases and condi- Enormous growth potential may be seen in pharmaceutical companies that are working to elimi- nate worldwide health crises such as malaria. lion in funding from MVI, which has received $100.7 million for vaccine development from theBill & Melinda Gates Foundation. The company’s malaria candidate vaccine (PfCP2.9) targets the world’s most deadly malaria parasite (Plasmodium falciparum) at its most destructive stage—its rapid replication in human red blood cells. If successful, it could and * blood cell regeneration. SinoBiomed is partnering with the World Health Organization (WHO) and the Malaria Vaccine help prevent malaria, which threatens 2 billion and kills more than 1 million people worldwide every year. SinoBiomed is extremely adept in developing and manufacturing recombinant protein drugs at very low cost. With first-rate scientists and advisors (many U.S. trained); strong international collaboration and funding; and strong intellectual property holdings and poten- Health (PATH) to develop and deliver drugs that could save hun- company offers both a rapid growth rate and immense domestic market potential. SinoBiomed hasreceived $2 mil- site at www.sinobiomed.com. tions, including: * malaria; hepatitis; * surgical bleeding; cancer; * rheumatoid arthritis; diabetic ulcers and burns; Initiative (MVI) of the Program for Appropriate Technology in dreds of millions of lives. To date, tial for future discoveries, the To learn more, visit the Web
